On 4 September 2026, KFM KINGDOM (03816.HK) issued an update on the unusual share price and trading volume fluctuations that day, confirming that, apart from its controlling shareholder KIG Real Estate still exploring cooperation possibilities including potential transactions involving its securities, the Board is not aware of any reason for the fluctuations; KIG Real Estate holds approximately 75.0% of the shares.
DUFU LIQUOR GP (00986.HK) plans to issue up to 25.89 million shares by placement, with estimated net proceeds of HKD 6.5 million.
NEW CONCEPTS (02221.HK) plans to issue in total 14.89 million shares.
On 4 September 2026, GENSCRIPT BIO (01548.HK) announced a proposal to spin off and separately list its indirect non-wholly-owned subsidiary Probio Technology (its biologics and advanced therapies CDMO business) on the Main Board of HKEX, with the Listing Committee having confirmed on 14 August 2026 that the Company may proceed; the Company will retain a controlling interest upon completion, eligible shareholders will be offered a guaranteed allocation, and the spin-off may or may not proceed.
On 4 September 2026, H WORLD-S (01179.HK) announced a proposed offering of RMB-denominated bonds to non-US persons in offshore transactions under Regulation S of the US Securities Act, with the principal amount, interest rate and maturity to be determined at pricing; the net proceeds are intended for general corporate purposes, and the bonds will not be registered under the Securities Act, with no assurance that the offering will be completed.
On 4 September 2026, INSILICO (03696.HK) announced that chairman and chief executive officer Dr. Aleksandrs Zavoronkovs has initiated a plan to purchase additional shares on the open market with his personal funds during September 2026, with an estimated aggregate amount of up to HKD 16 million; the Company is expected to maintain a sufficient public float after implementation of the plan.
On 3 September 2026, EDICO HOLDINGS (08450.HK) made supplemental disclosures on its trading card business: confirming that financial printing remains the Group's principal business (no scaling-down plan within the next 12 months, with interim revenue up 47.1% to approximately HKD 12.6 million), disclosing internal control measures and funding caps for HKTCG, and clarifying media reports that the approximately HKD 80 million of cards displayed include personal collections still owned by their owners, and that the approximately HKD 60 million represents an estimate of potential resources for HKTCG's future development rather than an actual capital contribution.
On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has approved the domestic registration and marketing of oteseconazole capsules (0.15g, Class 4 chemical drug) developed by its subsidiary Chengdu Shengdi, for the treatment of severe vulvovaginal candidiasis (VVC); the drug is an oral small-molecule fungal CYP51 inhibitor introduced from the US company Mycovia, and this approval covers the transfer of the overseas-produced drug to domestic production.
On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has accepted the marketing application for Zhuotuoqibai injection (SHR-1819), an IL-4Rα-targeting antibody independently developed by its subsidiary Guangdong Hengrui, for moderate to severe atopic dermatitis in adults; the Phase III study (652 patients) met both co-primary efficacy endpoints with results significantly superior to placebo.
On 3 September 2026, HENGRUI PHARMA (01276.HK) announced that the NMPA has accepted the marketing application for HRS-7535 tablets, an oral small-molecule GLP-1 receptor agonist developed by its subsidiary Shandong Shengdi, for long-term weight management in adults (obesity or overweight with comorbidities); the pivotal Phase III study showed an average weight reduction of up to 11.1% in the 180mg group at week 50.
On 4 September 2026, TENCENT MUSIC-SW (01698.HK) announced the pricing of its public offering of USD 1 billion senior unsecured notes in two tranches — USD 500 million at 5.050% due 2031 and USD 500 million at 5.650% due 2036 — with expected net proceeds of approximately USD 991.9 million for offshore debt refinancing and share repurchases; the notes are expected to be listed on HKEX.
On 3 September 2026, CIRC (01763.HK) announced that the coupon rate of its 2026 sci-tech innovation corporate bonds to professional investors (Tranche 1, with an issue size of no more than RMB 500 million and a three-year tenor) has been determined at 1.50% following bookkeeping, with the offline issue scheduled for 4 and 7 September.
On 3 September 2026, SIMCERE PHARMA (02096.HK) announced that Yimule (Kulaiweibai injection), a domestic Class 1 innovative biologic developed in strategic cooperation with Ruiyang, has been approved by the NMPA for marketing in China, for the prevention of RSV-associated lower respiratory tract infection in neonates and infants; Phase III data showed 85.32% protective efficacy against RSV-associated lower respiratory tract infection requiring medical intervention and 83.27% against RSV-associated hospitalisation at 150 days after administration.
On 3 September 2026, GOLDEN FAITH GP (02863.HK) announced that chairman and executive director Mr. Ko Chun Hei has placed his entire shareholding of 119,595,000 shares (approximately 17.34%) through a placing agent, and no longer holds any shares after completion; all placees are independent third parties, and no single placee may hold 30% or more of the issued share capital after the placing.
On 4 September 2026, GANFENGLITHIUM (01772.HK) announced that the reduction plan of vice president Mr. Fu Lihua (up to 40,000 shares, during 4 June to 3 September 2026) has expired without implementation, with his holding unchanged at 215,050 shares (0.010% of the total share capital).
On September 3, 2026, FUTURE BRIGHT (00703.HK) announced that its wholly-owned subsidiary Chun Ying had entered into two renovation contracts with an independent contractor for its Edo Japanese Restaurant, with lump-sum contract prices of MOP 1,130,000 (approximately HKD 1,096,100) and MOP 13,300,000 (approximately HKD 12,901,000), covering civil and waterproofing works and premium decoration and electrical and mechanical installation works respectively, with the latter expected to be completed in the fourth quarter of 2026. Aggregated under the Listing Rules, the two contracts constitute a discloseable transaction exempt from the circular and shareholders' approval requirements.
